BioSpace News Archive

BioMidwest

The Association of Black Cardiologists collaborating with Quantum Genomics’ NEW-HOPE Study, incorporating minority inclusivity, presents Late-Breaking Trial success of novel antihypertensive agent

Firibastat meets primary endpoint and demonstrates highly significant and clinically relevant efficacy in lowering blood pressure in a diverse population whose hypertension is typically difficult to treat

November 10, 2018
·
4 min read
Drug Development

Forxiga significantly reduced hospitalisation for heart failure or CV death in a broad patient population with type-2 diabetes in the landmark DECLARE-TIMI 58 trial

Fewer MACE events observed with Forxiga vs. placebo, but this finding did not reach statistical significance

November 10, 2018
·
5 min read
Biotech Bay

Cardiva Medical Announces Positive Results of the AMBULATE Pivotal Study Evaluating the VASCADE MVP System Compared to Manual Compression for Multi-Vessel Closure Following Electrophysiology Procedures

The AMBULATE pivotal study met its primary efficacy endpoint. The median time to patients getting on their feet following arrhythmia ablation procedures was reduced by 3.9 hours.

November 10, 2018
·
5 min read
Drug Development

Infinity Reports Clinical and Translational Data from Expansion Cohorts of MARIO‑1 Phase 1b Study of IPI-549 in Combination with Opdivo® (nivolumab) at SITC’s 33rd Annual Meeting

Clinical Activity and Translational Data from IPI-549 in Monotherapy and in Combination with Opdivo Support On-Mechanism Proof of Concept

November 10, 2018
·
13 min read
Business

MedEquities Realty Trust Signs Agreement To Re-Tenant Texas Skilled Nursing Portfolio

MedEquities Realty Trust, Inc. announced that it has signed a new, 15-year triple net lease with Creative Solutions in Healthcare (“Creative Solutions”), a regional skilled nursing and assisted living facility operator based in Fort Worth, Texas, for all 10 of the Company’s locations currently leased to affiliates of OnPointe

November 10, 2018
·
3 min read
Drug Development

Brooklyn ImmunoTherapeutics Announces Presentation of Positive Results of IRX-2 Therapy in Resectable Breast Cancer and Head and Neck Cancer at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer

Statistically significant increase in tumor-infiltrating lymphocytes reported

November 10, 2018
·
4 min read
Drug Development

FARXIGA Significantly Reduced Hospitalization for Heart Failure or CV Death in a Broad Patient Population with Type 2 Diabetes in the Landmark DECLARE-TIMI 58 Trial

Fewer MACE events observed with FARXIGA vs. placebo, but this finding did not reach statistical significance

November 10, 2018
·
9 min read